NCT00097760 - Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Natalizumab

Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.

DRUG

Natalizumab

Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.

DRUG

Placebo

Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.